Ratio Therapeutics Enters License And Collaboration Agreement With Novartis For SSTR2-Targeting Radiotherapeutic Candidate; Under The Terms Of The Agreement, Ratio Will Receive Combined Upfront And Potential Milestone Payments Up To $745M